1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. UCB
  6. Summary
    UCB   BE0003739530

UCB

(UCB)
  Report
Real-time Euronext Bruxelles  -  11:35 2022-08-09 am EDT
74.18 EUR   +1.45%
08/05UCB : Transparency notification FMR LLC
PU
08/05UCB : Disposal of own shares
PU
07/28UCB HY2022 FINANCIAL RESULTS : Strong performance, resilience and delivery
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Bruxelles
08/03/2022 08/04/2022 08/05/2022 08/08/2022 08/09/2022 Date
73.96(c) 73.66(c) 73.72(c) 73.12(c) 74.18 Last
336 965 320 347 277 855 287 903 203 313 Volume
+0.03% -0.41% +0.08% -0.81% +1.45% Change
More quotes
Estimated financial data (e)
Sales 2022 5 339 M 5 456 M 5 456 M
Net income 2022 498 M 509 M 509 M
Net Debt 2022 2 445 M 2 499 M 2 499 M
P/E ratio 2022 26,3x
Yield 2022 1,84%
Sales 2023 5 406 M 5 525 M 5 525 M
Net income 2023 598 M 611 M 611 M
Net Debt 2023 1 910 M 1 952 M 1 952 M
P/E ratio 2023 20,7x
Yield 2023 1,91%
Capitalization 13 890 M 14 195 M 14 195 M
EV / Sales 2022 3,06x
EV / Sales 2023 2,92x
Nbr of Employees 8 600
Free-Float 62,1%
More Financials
Company
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. 
Sector
Pharmaceuticals
Calendar
02/23Earnings Release
More about the company
Ratings of UCB
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A
More Ratings
All news about UCB
08/05UCB : Transparency notification FMR LLC
PU
08/05UCB : Disposal of own shares
PU
07/28UCB HY2022 FINANCIAL RESULTS : Strong performance, resilience and delivery
PU
07/28UCB : Strong first six months – UCB with continued delivery and strong resilience
PU
07/28UCB : Press Release
CO
07/28UCB : Half-year report
CO
07/28UCB : Half-year results
CO
07/28UCB SA Reports Earnings Results for the Half Year Ended June 30, 2022
CI
07/20UCB : Acquisition and disposal of own shares
PU
07/20UCB : Capturing real-world data and evidence in clinical trials
PU
07/20UCB : Share buyback
CO
07/15UCB : Acquisition and disposal of own shares
PU
07/15Aurinia Pharmaceuticals Names New Chief Commercial Officer As Colao Leaving; Shares Sin..
MT
07/15UCB : Share buyback
CO
07/14Aurinia Pharmaceuticals Appoints Scott Habig Chief Commercial Officer
MT
More news
News in other languages on UCB
08/01Deutsche Bank verlaagt koersdoel UCB
07/30WEEK : Bel20 wint bijna 2 procent
07/29UCB : Financial Reporting Document
07/29UCB : Financial Reporting Document
07/29BOLSA DE MADRID : ¿Malas noticias? ¡Buenas noticias!
More news
Analyst Recommendations on UCB
More recommendations
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends UCB
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 73,12 €
Average target price 102,71 €
Spread / Average Target 40,5%
EPS Revisions
Managers and Directors
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Sandrine Dufour Chief Financial Officer & Executive Vice President
Stefan Oschmann Chairman
Iris Löw-Friedrich Chief Medical Officer, EVP & Head-Development
Dhavalkumar Patel Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
UCB-27.14%14 195
CSL LIMITED1.69%99 686
SAMSUNG BIOLOGICS CO.,LTD.-0.33%49 292
WUXI BIOLOGICS (CAYMAN) INC.-20.10%40 173
BIOGEN INC.-9.05%31 571
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-22.19%22 977